Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open‐label, phase 1/2 study
Journal article published in 2019 by
Torben Plesner 
,
Hendrik‐Tobias Arkenau,
Francesca Gay ,
Monique C. Minnema,
Mario Boccadoro,
Philippe Moreau ,
Jamie Cavenagh,
Aurore Perrot,
Jacob P. Laubach ,
Jakub Krejcik,
Tahamtan Ahmadi,
Carla de Boer,
Diana Chen,
Christopher Chiu,
Jordan M. Schecter
and other authors.
,
Hendrik‐Tobias Arkenau,
Francesca Gay ,
Monique C. Minnema,
Mario Boccadoro,
Philippe Moreau ,
Jamie Cavenagh,
Aurore Perrot,
Jacob P. Laubach ,
Jakub Krejcik,
Tahamtan Ahmadi,
Carla de Boer,
Diana Chen,
Christopher Chiu,
Jordan M. Schecter
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 